CPA
SAGE icon

Capital Performance Advisors’s Sage Therapeutics SAGE Stock Holding History

Capital Performance Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-502
Closed -$3.62K – 2188
2024
Q3 		$3.62K Buy
+502
New +$4.6K ﹤0.01% 1262

Other funds holding SAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Capital Performance Advisors's SAGE Position: Q4 2024 in Review

Capital Performance Advisors sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 502 shares — an estimated $3.62K sold.

Capital Performance Advisors first reported a position in SAGE in Q3 2024 and held it in 1 quarter. The position peaked at $3.62K in Q3 2024. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • Capital Performance Advisors reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 502 Sage Therapeutics shares in Q4 2024, an estimated $3.62K.
  • Capital Performance Advisors first reported a position in Sage Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Sage Therapeutics position peaked at $3.62K in Q3 2024.
  • 177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.